

| iPSC | Line: | |
|------|-------|--|
| | | |

Cedars-Sinai RMI Induced Pluripotent Stem Cell (iPSC) Core Certificate of Analysis (COA)

| Cell Line Name | |
|-----------------|--|
| CS Vial ID #(s) | |
| Date Vialed | |
| Passage Number | |

The following testing specifications have been met for the specified cell line:

| Test Description | Test Specification | Result |
|--|---|--------|
| Mycoplasma | No contamination detected | |
| Alkaline Phosphatase Staining | Positive AP staining | |
| Karyotype by G-Banding | Normal Karyotype | |
| Pluripotency | | |
| PrimeView Global Gene Expression Profile Assay (<u>PluriTest</u>) | Pluripotency score ≥ 20 and novelty score ≤ 1.6 | |
| Immunocytochemistry (IF-IC) | OCT3/4, NANOG, SOX2, TRA-1-60, TRA-1-81, SSEA4 | |
| <u>TaqMan® hPSC Scorecard™ Assay</u> | Confirm appropriate expression of self-renewal factors | |
| Differentiation | | |
| EB Formation | Successful Embryoid Body (EB) formation after 14 days | |
| TaqMan® hPSC Scorecard™ Assay | Tri-lineage differentiation potential | |
| | Endoderm, Ectoderm and Mesoderm | |
| Reprogramming Plasmid Integration | | |
| Genomic DNA PCR | Confirm the presence or absence of exogenous reprogramming plasmids | |
| Parent Cell Line Lineage Determinat | ion | |
| TCRB + TCRG T-Cell Clonality Assay | Confirm presence or absence of clonal T-cell receptor beta | |
| (Blood derived cell lines only) | chain and gamma chain gene rearrangements in iPSCs | |
| Cell Line Authentication | | |
| <u>STR Analysis</u> | Confirm identity matching score is above 80% | |

DHRUV SAREEN, Ph.D CORE DIRECTOR



CONTACT INFORMATION:

| Core Director: Dhruv Sareen, Ph.D. | Institution: Cedars-Sinai RMI Induced Pluripotent Stem Cell Core | |
|---------------------------------------|--|-------------|
| Phone Number: (310) 423-7074 | Address: 8700 Beverly Blvd. AHSP 8500 | |
| Email Address: iPSCCore@cshs.org | Los Angeles, CA 90048 USA | |
| PARENT LINE IDENTIFICATION | N AND INFORMATION: | |
| Parent Cell Line: | | |
| Age at Tissue Sampling: | | |
| Phenotypic Sex: | Male | Female |
| Clinical Diagnosis (if known): | | |
| Specific Mutations (if known): | | |
| Additional Information: | | |
| | | |
| | ATIONI. | |
| REPROGRAMMING INFORMA | ATION. | |
| iPSC Line Name: | | |
| Vial ID(s): | | |
| Starting Cell Type: | PBMC Fibroblast Other: | . <u> </u> |
| | Episomal Sendai Virus Other: | |
| Reprogramming Factors: | Oct3/4 Sox2 KLF4 L-Myc | shp53 Lin28 |
| Other: | | |
| CULTURING INFORMATION: MEDIUM: | | |
| Growth Medium: | | |
| Company: | | |
| Catalog #: | | |

iPSC Line: _____



| SUBSTRATE: Substrate Specification: Company: Catalog #: Coating Concentration: PASSAGING METHOD: | | | |
|--|------------------------|--------------------|------------|
| Method: | STEMPRO EZPassage Tool | Versene (EDTA) | ReLeSR |
| Passaging Frequency: Average Split Ratio: Cell Line Preferred Method: | 7 days | 7 days | 7 days |
| Rate of Differentiation: Freezing Media: | High (≥50%) | Moderate (30-40%) | Low (≤20%) |
| Recovery Media: | | | |
| CHARACTERIZATION OF UN G-BAND KARYOTYPE: Performed By: Passage Number: Karyotyping Analysis & Results Interpretation: | | OTENT CELL LINE: | |
| Comments: | | | |
| PLURITEST: | | | |
| Final Result: Pluripotency Score: Novelty Score: | Pass Fail | _ Further Evaluate | TBD N/A |

iPSC Line: _____



| A AA ALIALOOVTOCLUSA ALCTOV | | | | | | | |
|--|---------------|----------|------------------------|--------------|-------------|------|----------|
| MMUNOCYTOCHEMISTRY: | AP | SSEA-4 | Tra-1-60 | Tra-1-81 | Nanog | Oct4 | Sox2 |
| Pluripotency Marker: | | | | | | | |
| | | | | | | • | - |
| PLASMID INTEGRATION ANAL | <u>.YSIS:</u> | | | | | | |
| bsence of plasmid integration coا آ | | | | | | | |
| | EBNA | Negative | El | BNA Positiv | ositive TBD | | |
| Result: | | | | | | | |
| Passage #: | | | | | | | |
| CLIADACTEDIZATION OF DIFFE | DENITIAT | | NITIAI - | | | | |
| CHARACTERIZATION OF DIFFE | | | | | | | |
| his cell line has been assessed fo | | | | | | | |
| 14 Day Embryoid Body Forma | tion | TaqMan | [®] hPSC Scor | ecard™ Ass | ay <u> </u> | PCR | |
| PSC SCORECARD DATA ANALYSIS: | , | | | | | | |
| | Self-Rei | newal | Endodern | n E | ctoderm | Me | soderm |
| iPSC (Day 0): | | | | | | | |
| Score: | | | | | | | |
| EBs (Day 14): | | | | | | | |
| Score: | | | | | | | |
| Comments: | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| PARENT CELL LINE LINEAGE D | ETERMIN | IATION: | | | | | |
| Blood derived cell lines only) | | | | | | | |
| | | TCR-αβ | | | TCR-γδ | | |
| T-Cell Clonality Assay: | Po | sitive | Negati | ve | Positive | | Negative |
| Final Result: | T-Cell | Derived | Non T | -Cell Derive | d T | BD | N/A |

iPSC Line: _____



| | REGENERATIVE MEDICINE INSTITUTE | | | | i | iPSC Line: | | | |
|--------------|---------------------------------|----------------|---------|--------|--------|------------|------|-----|--|
| SELL LINE | | ATIONI | | | | | | | |
| LELL LINE / | AUTHENTIC | ATION: | | | | | | | |
| Parent Cell | Line: | | | | | | | | |
| AMEL | CSF1PO | D13S317 | D16S539 | D5S818 | D7S820 | TH01 | TPOX | vWA | |
| | | | | | | | | | |
| iPSC Line: | | | | | | | | | |
| AMEL | CSF1PO | D13S317 | D16S539 | D5S818 | D7S820 | TH01 | TPOX | vWA | |
| | | | | | | | | | |
| | | | | | | | | | |
| % Identity I | Match: | | | | | | | | |
| IDEXX IBR # | t(s): | | | | | | | | |
| | | | | | | | | | |
| ADDITIONA | AL INFORMA | <u> ATION:</u> | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |